Norepinephrine Infusion Rate for Hepatorenal Syndrome
For a norepinephrine drip containing 10 mg in 90 mL normal saline (concentration: 111 mcg/mL), start at 3-5 mL/hr and titrate upward every 4 hours by 3-5 mL/hr increments until mean arterial pressure increases by at least 10 mmHg or urine output exceeds 200 mL per 4 hours, with a maximum rate of approximately 24 mL/hr.
Dosing Algorithm
Your prepared concentration is 111 mcg/mL (10,000 mcg ÷ 90 mL).
Starting Dose
- Initial rate: 3-5 mL/hr (equivalent to 0.5 mg/hr or approximately 7 mcg/min in a 70-kg adult)
- This aligns with the standard starting dose of 0.5 mg/hour recommended for hepatorenal syndrome 1
Titration Protocol
- Increase by 3-5 mL/hr every 4 hours if targets not met
- Target goals:
- Mean arterial pressure increase ≥10 mmHg from baseline, OR
- Urine output >200 mL per 4-hour period 1
Maximum Dose
- Maximum rate: approximately 24 mL/hr (equivalent to 3 mg/hr or 2,664 mcg total)
- This represents the upper limit of 3 mg/hour cited in guidelines 1
Clinical Context
Norepinephrine is an effective alternative to terlipressin for hepatorenal syndrome-AKI and may be preferred in patients with shock 2, 1. Recent evidence demonstrates that norepinephrine achieves HRS reversal in 57-83% of patients 3, 4, 5, with efficacy comparable to terlipressin 4, 6.
Key Management Points
Always administer with albumin:
- Give albumin 20-40 g/day concurrently 1
- Initial albumin dose of 1 g/kg (maximum 100 g) on day 1 is recommended for volume expansion 2
Monitoring requirements:
- Continuous hemodynamic monitoring is essential 7, 8
- Check blood pressure and pulse every minute initially if intensive monitoring unavailable 9
- Central venous pressure should be maintained between 4-10 mmHg when possible 1
- Preferably administer through central venous access to minimize extravasation risk 7, 8
Treatment duration:
- Continue for up to 14 days or until serum creatinine returns to baseline 1
- If no improvement in creatinine after 4 days at maximum tolerated dose, consider discontinuation 1
Critical Caveats
Norepinephrine requires ICU-level care due to the need for continuous infusion and intensive monitoring 1. Unlike terlipressin, it cannot be administered on general medical wards.
Watch for adverse effects:
- Cardiovascular complications (chest pain, ischemia) occur more commonly with norepinephrine than terlipressin 10, 6
- Tissue necrosis from extravasation—if this occurs, infiltrate the site with 5-10 mg phentolamine diluted in 10-15 mL saline immediately 7
- Discontinue if serious arrhythmias develop 8
Predictors of response:
- Lower baseline MELD score predicts better response 4
- Adequate MAP increase (median 16 mmHg) correlates with successful diuresis and renal recovery 11
- Initial bilirubin levels and INR values may differ between responders and non-responders 12
Practical Considerations
Your specific concentration (111 mcg/mL) is more dilute than standard ICU preparations, which typically use 4 mcg/mL (1 mg in 250 mL) or 16 mcg/mL (4 mg in 250 mL) 7, 8. This means you'll need higher mL/hr rates but have better precision for titration.
Cost and availability favor norepinephrine: Studies consistently show norepinephrine is significantly less expensive than terlipressin (approximately USD 350 vs. 750 for treatment course) 10, 4, and it's more readily available in most tertiary care centers 12, 13.
Recent evidence suggests norepinephrine may be superior to midodrine/octreotide: A 2021 randomized trial showed 57.6% response rate with norepinephrine versus only 20% with midodrine/octreotide 3, leading experts to recommend abandoning midodrine/octreotide due to lack of efficacy 13.